Skip To Main Content

Cyramza ® (ramucirumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Cyramza Summary of Product Characteristics (SmPC)

Cyramza® (ramucirumab): Use in patients with COVID-19 (Coronavirus disease 2019)

The use of Cyramza (ramucirumab) in patients with COVID-19 has not been studied.

Ramucirumab Treatment and Coronavirus (COVID-19)

COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1

Eli Lilly and Company has not studied the use of ramucirumab in patients with COVID-19 nor specifically in patients at risk of contracting COVID-19.

Potential Risk and Benefit Considerations

Treating physicians should assess the patient’s individual benefit/risk ratio considering the patient's signs and symptoms, prior medical history, concomitant medications, and other individual factors when making ramucirumab treatment decisions in the context of COVID-19. Ramucirumab dose adjustments, made at the physician’s discretion, should follow the label. Supportive treatment should be provided as clinically indicated and patients monitored appropriately. Drug interactions between ramucirumab and potential COVID-19 treatments should be considered and are described below.2

Drug Interactions

The following medications are not expected to have a clinically relevant effect on ramucirumab exposure and ramucirumab is not expected to have a clinically relevant effect on the exposure of the following potential-COVID-19 medications

  • hydroxychloroquine

  • chloroquine

  • remdesivir

  • favipiravir

  • ritonavir

  • lopinavir, or

  • azithromycin.2

Infectious Disease Resources for COVID-19

For the most current information regarding COVID-19, please refer to the following resources: 

References

1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Coronavirus disease (COVID-19) outbreak. World Health Organization Europe. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov

4. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china

5. European Society for Medical Oncology. Accessed March 23th. https://www.esmo.org/newsroom/covid-19-and-cancer/covid-19-useful-resources

6. [NICE] National Institute for Health and Care Excellence. Coronavirus (COVID-19). Available from: https://www.nice.org.uk/covid-19. Accessed 25 March 2020.

Glossary

CDC = Centers for Disease Control and Prevention

COVID-19 = coronavirus disease 2019

NCCN = National Comprehensive Cancer Network

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

WHO = World Health Organization

Date of Last Review: March 17, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

 If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request